520 related articles for article (PubMed ID: 17413981)
41. Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours.
Fauvet R; Dufournet C; Poncelet C; Uzan C; Hugol D; Daraï E
J Surg Oncol; 2005 Dec; 92(4):337-43. PubMed ID: 16299808
[TBL] [Abstract][Full Text] [Related]
42. Loss of DCC gene expression during ovarian tumorigenesis: relation to tumour differentiation and progression.
Saegusa M; Machida D; Okayasu I
Br J Cancer; 2000 Feb; 82(3):571-8. PubMed ID: 10682668
[TBL] [Abstract][Full Text] [Related]
43. Nuclear expression of apurinic/apyrimidinic endonuclease increases with progression of ovarian carcinomas.
Tanner B; Grimme S; Schiffer I; Heimerdinger C; Schmidt M; Dutkowski P; Neubert S; Oesch F; Franzen A; Kölbl H; Fritz G; Kaina B; Hengstler JG
Gynecol Oncol; 2004 Feb; 92(2):568-77. PubMed ID: 14766249
[TBL] [Abstract][Full Text] [Related]
44. Interphase cytogenetic analysis of serous ovarian tumors of low malignant potential: comparison with serous cystadenomas and invasive serous carcinomas.
Diebold J; Deisenhofer I; Baretton GB; Blasenbreu S; Suchy B; Schneiderbanger K; Meier W; Haas CJ; Löhrs U
Lab Invest; 1996 Oct; 75(4):473-85. PubMed ID: 8874380
[TBL] [Abstract][Full Text] [Related]
45. Immunohistochemical staining for Ki-67 antigen, carcinoembryonic antigen, and p53 in the differential diagnosis of glandular lesions of the cervix.
Cina SJ; Richardson MS; Austin RM; Kurman RJ
Mod Pathol; 1997 Mar; 10(3):176-80. PubMed ID: 9071723
[TBL] [Abstract][Full Text] [Related]
46. Nested variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 12 cases.
Lin O; Cardillo M; Dalbagni G; Linkov I; Hutchinson B; Reuter VE
Mod Pathol; 2003 Dec; 16(12):1289-98. PubMed ID: 14681330
[TBL] [Abstract][Full Text] [Related]
47. Apoptosis in epithelial ovarian tumours Prognostic significance of clinical and histopathologic factors and its association with the immunohistochemical expression of apoptotic regulatory proteins (p53, bcl-2 and bax).
de la Torre FJ; García A; Gil-Moreno A; Planaguma J; Reventos J; Ramón y Cajal S; Xercavins J
Eur J Obstet Gynecol Reprod Biol; 2007 Jan; 130(1):121-8. PubMed ID: 16876311
[TBL] [Abstract][Full Text] [Related]
48. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia.
Kalir T; Wang BY; Goldfischer M; Haber RS; Reder I; Demopoulos R; Cohen CJ; Burstein DE
Cancer; 2002 Feb; 94(4):1078-82. PubMed ID: 11920478
[TBL] [Abstract][Full Text] [Related]
49. Poly(ADP-ribose) polymerase-1 regulates the stability of the wild-type p53 protein.
Wesierska-Gadek J; Schmid G
Cell Mol Biol Lett; 2001; 6(2):117-40. PubMed ID: 11544635
[TBL] [Abstract][Full Text] [Related]
50. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.
Chiesa-Vottero AG; Malpica A; Deavers MT; Broaddus R; Nuovo GJ; Silva EG
Int J Gynecol Pathol; 2007 Jul; 26(3):328-33. PubMed ID: 17581420
[TBL] [Abstract][Full Text] [Related]
51. Comparison of p53, Ki-67, and CD44v6 expression between primary and matched metastatic lesions in ovarian cancer.
Sakai K; Kaku T; Kamura T; Kinukawa N; Amada S; Shigematsu T; Hirakawa T; Kobayashi H; Ariyoshi K; Nakano H
Gynecol Oncol; 1999 Mar; 72(3):360-6. PubMed ID: 10053108
[TBL] [Abstract][Full Text] [Related]
52. [Comparative studies on the biological significance of the marker for proliferation Ki-67-Antigen and PCNA in primary ovarian carcinoma].
Reitmaier M; Rudlowski C; Biesterfeld S; Rath W; Schröder W
Zentralbl Gynakol; 2000; 122(7):361-7. PubMed ID: 10951706
[TBL] [Abstract][Full Text] [Related]
53. u-PA expression in benign, borderline and malignant ovarian tumors.
Kiziridou AD; Toliou T; Stefanou D; Agnantis N
Anticancer Res; 2002; 22(2A):985-90. PubMed ID: 12014682
[TBL] [Abstract][Full Text] [Related]
54. Metallothionein expression and nuclear size in benign, borderline, and malignant serous ovarian tumours.
Tan Y; Sinniah R; Bay BH; Singh G
J Pathol; 1999 Sep; 189(1):60-5. PubMed ID: 10451489
[TBL] [Abstract][Full Text] [Related]
55. Immunoexpression of CAS protein is augmented in high grade serous ovarian tumors.
Stawerski P; Wągrowska-Danilewicz M; Stasikowska O; Danilewicz M
Pol J Pathol; 2010; 61(4):219-23. PubMed ID: 21290345
[TBL] [Abstract][Full Text] [Related]
56. Prognostic significance of HLA-DR antigen in serous ovarian tumors.
Tamiolakis D; Kotini A; Venizelos J; Jivannakis T; Simopoulos C; Papadopoulos N
Clin Exp Med; 2003 Sep; 3(2):113-8. PubMed ID: 14598186
[TBL] [Abstract][Full Text] [Related]
57. Prognostic value of p53 and Ki-67 expression in resected or biopsy specimens of bile duct carcinoma.
Murakami M; Sasaki T; Kuwada Y; Yamasaki S; Kuwahara K; Chayama K
Oncol Rep; 2003; 10(5):1091-6. PubMed ID: 12883663
[TBL] [Abstract][Full Text] [Related]
58. Incidence of apoptosis, cell proliferation and P53 expression in renal cell carcinomas.
Tannapfel A; Hahn HA; Katalinic A; Fietkau RJ; Kühn R; Wittekind CW
Anticancer Res; 1997; 17(2A):1155-62. PubMed ID: 9137464
[TBL] [Abstract][Full Text] [Related]
59. [Expression and clinical relevance of ARHI, STAT3 and E2F1 in ovarian serous carcinoma].
Zhang J; Li YH; Cui AR; Wang JL; Cheng JX; Wang SJ
Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):905-9. PubMed ID: 19173990
[TBL] [Abstract][Full Text] [Related]
60. Prophylactic oophorectomy: a morphologic and immunohistochemical study.
Schlosshauer PW; Cohen CJ; Penault-Llorca F; Miranda CR; Bignon YJ; Dauplat J; Deligdisch L
Cancer; 2003 Dec; 98(12):2599-606. PubMed ID: 14669279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
